Generic Medicine Info
Indications and Dosage
Adult: As hydrochloride: Instil in the eye as 2% eye drops.

Mild heart failure
Adult: 100-200 mg bid-tid.
Oral: Severe heart failure, phaeochromocytoma. Ophthalmic: Angle-closure glaucoma.
Special Precautions
CV diseases; hyperthyroidism; DM; elderly; pregnancy, lactation; prostate disorders; occlusive vascular disease; cardiac arrhythmias.
Adverse Reactions
Palpitations, tachycardia, arrhythmias, reflex bradycardia. Hypotension, dizziness, fainting. Anxiety, fear, restlessness, insomnia, confusion, irritability, headache, psychotic symptoms. Dyspnoea, weakness, anorexia, nausea, vomiting. Mydriasis, difficulty in micturition and urinary retention, piloerection, sweating, increased salivation. Hyperglycaemia. Hypokalaemia and muscle tremor.
Drug Interactions
Increased cardiac effects with volatile anaesthetics, thyroid hormones, cardiac glycosides and antiarrhythmics. Additive hypotensive effects with antihypertensives. Severe hypotension may occur with guanethidine. Increased risk of hypotension and tachycardia with α-blockers. Increased risk of hypertension with nonselective β-beta blockers. Increased risk of hypertension and arrhythmias with TCAs. Additive CV toxicity with levodopa, bromocriptine.
Potentially Fatal: Increased risk of mortality with amiodarone (although interaction is not established).
Mechanism of Action: Ibopamine is a peripheral dopamine agonist with vasodilating properties and a weak positive inotropic effect. It stimulates α- and β-adrenoceptors at high concentrations.
Absorption: Peak plasma concentrations after 30 min (oral).
Metabolism: Rapidly converted to epinene (active metabolite) by esterase hydrolysis.
MIMS Class
Cardiac Drugs / Mydriatic Drugs
Disclaimer: This information is independently developed by MIMS based on Ibopamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in